Clinical Trials Logo

Clinical Trial Summary

This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00175929
Study type Interventional
Source UCB Pharma
Contact
Status Completed
Phase Phase 2
Start date May 2005
Completion date March 2006

See also
  Status Clinical Trial Phase
Completed NCT00433667 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Completed NCT00425282 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Active, not recruiting NCT03916848 - Novel Network Analysis of Intracranial Stereoelectroencephalography N/A
Recruiting NCT04383028 - MELD as an Adjunct for SEEG Trajectories N/A